Pfizer (NYSE:PFE) Stock Price Down 1.7% – Here’s Why

Pfizer Inc. (NYSE:PFE)’s share price traded down 1.7% during trading on Friday . The company traded as low as $25.24 and last traded at $25.3090. 36,875,136 shares changed hands during mid-day trading, a decline of 13% from the average session volume of 42,449,098 shares. The stock had previously closed at $25.75.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer announced a Europe label expansion for its hemophilia therapy Hympavzi, which could broaden the drug’s commercial opportunity and support long-term revenue growth.
• Positive Sentiment: Multiple updates highlighted ongoing clinical and development activity, including a new Korea migraine study for Nurtec ODT, a Phase 1 food-effect study for PF-07799933, a prazosin site-transfer trial, and a planned Japan RSV vaccine trial. These reinforce Pfizer’s pipeline and global expansion efforts.
• Positive Sentiment: Recent commentary around Pfizer’s Q1 earnings pointed to improving momentum in new and acquired products, especially oncology and migraine treatments, as well as progress from the Seagen integration and legal settlements that may improve clarity around future cash flow.
• Neutral Sentiment: Media coverage also noted that investor sentiment remains mixed, with some analysts and commentators arguing Pfizer still lacks strong earnings momentum and is being supported more by its dividend and defensive valuation than by a clear near-term growth catalyst.
• Negative Sentiment: Pfizer continues to face concerns about declining COVID-related sales and looming patent expirations, which have weighed on the stock even after earnings beat expectations.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Zacks Research raised Pfizer from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. Wall Street Zen raised Pfizer from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Argus raised Pfizer from a “hold” rating to a “buy” rating and set a $35.00 target price on the stock in a report on Monday, March 2nd. Citigroup raised their target price on Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a report on Wednesday, April 29th. Finally, Wolfe Research reissued an “underperform” rating and set a $26.00 price target on shares of Pfizer in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $28.84.

Pfizer Trading Down 1.7%

The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The stock has a fifty day simple moving average of $26.98 and a 200 day simple moving average of $26.19. The firm has a market capitalization of $144.25 billion, a P/E ratio of 19.32 and a beta of 0.35.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The business had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period last year, the firm earned $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, research analysts forecast that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a yield of 6.8%. Pfizer’s dividend payout ratio (DPR) is currently 131.30%.

Institutional Investors Weigh In On Pfizer

Several large investors have recently made changes to their positions in PFE. Norges Bank bought a new stake in shares of Pfizer in the fourth quarter worth about $1,830,986,000. Morgan Stanley increased its holdings in shares of Pfizer by 19.2% in the fourth quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock worth $2,218,929,000 after purchasing an additional 14,342,946 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Pfizer by 38.9% in the fourth quarter. Bank of New York Mellon Corp now owns 48,514,971 shares of the biopharmaceutical company’s stock worth $1,208,023,000 after purchasing an additional 13,581,757 shares during the last quarter. Franklin Resources Inc. increased its holdings in shares of Pfizer by 47.8% in the third quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company’s stock worth $638,787,000 after purchasing an additional 8,108,887 shares during the last quarter. Finally, Janus Henderson Group PLC increased its holdings in shares of Pfizer by 577.5% in the fourth quarter. Janus Henderson Group PLC now owns 8,786,084 shares of the biopharmaceutical company’s stock worth $218,817,000 after purchasing an additional 7,489,189 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.